In this study, we demonstrated that the G9a inhibitor attenuated not only MGO-induced peritoneal fibrosis, but also TGF-β1-stimulated fibrotic changes in HPMCs. This evidence concerns the gene TGFB1 and Peritoneal Fibrosis.